Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo在肝臟大會上重點介紹了FXR314在MASH的2期結果,顯示與其他FXR激動劑相比,具有顯著的降低肝脂和改善安全性的優勢
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo在肝臟大會上重點介紹了FXR314在MASH的2期結果,顯示與其他FXR激動劑相比,具有顯著的降低肝脂和改善安全性的優勢